We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Embryonic Development “In a Dish” – Recreating Two Key Processes

By LabMedica International staff writers
Posted on 21 Oct 2015
In a biotechnological advancement involving human pluripotent stem cells (h-PSCs) and geometric restriction, researchers have for the first time developed animal-free platforms to help screen for and study drugs that cause birth defects.

A team led by Prof. More...
Hanry Yu , principal research scientist at the Institute of Bioengineering and Nanotechnology (IBN; Singapore) of Singapore’s Agency for Science, Technology, and Research (A*STAR), has developed a cell-based model that largely recreates two key processes essential for fetal formation. The researchers not only controlled differentiation of stem cells into other cell types, but have also achieved a successful migration of these transformed cells. The latter has remained elusive to researchers until now and makes it possible to build a better embryo development model for drug testing.

IBN Executive Director Prof. Jackie Y. Ying said, “Unintended exposure to compounds that can disrupt fetal development, such as thalidomide, may lead to birth defects or even miscarriage. Our breakthrough is a major step toward identifying such compounds and understanding how they affect embryonic growth, and we hope that it will eventually help to mitigate the risk of fetal exposure to these destructive agents.”

Currently, researchers rely on animal testing to assess the hazard of teratogens, but this is expensive, time-consuming, unreliable due to inter-species variability, and involves ethical concerns. To overcome these problems, researchers have focused on developing alternative tests using h-PSCs. Prof. Yu explained, “Embryonic development does not only consist of the transformation of stem cells into other cell types, such as bone, muscle, or nerve cells. It also involves the migration of these transformed cells to the right places in the body where they will develop into properly functioning organs as intended. This is why we believed it was important to develop a model encompassing both cell differentiation and migration that would give us a more complete and accurate picture of the effects of teratogens on the developing embryo.”

In the new model, the researchers confined the environment in which the embryonic stem cells transformed into other cell types, and restricted the ensuing migration of the micropatterned h-PSC colonies so that the resulting mesoendoderm cells would form a consistent circular or ring pattern. Due to this geometric restriction, it was possible for the researchers to study the effect of teratogens, which may alter the shape and even the eventual position of the mesoendoderm layer.

“A key feature of our model that would facilitate its application as a drug screening platform is the consistency with which we can generate the circular mesoendoderm layer. This provides a reliable starting point and straightforward indicator for measuring drug-induced effects,” shared Prof. Yu.

They also developed image processing and statistical algorithms to quantify and classify the teratogenic potential of different compounds. Using their micropatterned h-PSC model, they have successfully distinguished between teratogenic compounds (i.e., thalidomide) and non-teratogenic compounds (i.e., penicillin G), and could also measure dose-dependent effects, which is essential for identifying clinically relevant dose.

The team is currently looking for clinical and industrial partners to further develop and validate their technology.

The study, by Xing J et al, was published online May 2015 in the journal Scientific Reports.

Related Links:

Institute of Bioengineering and Nanotechnology



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.